Tyra Biosciences, Inc. TYRA
We take great care to ensure that the data presented and summarized in this overview for Tyra Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TYRA
View all-
Ra Capital Management, L.P. Boston, MA12.2MShares$174 Million2.55% of portfolio
-
Alta Partners Management Company, L.P. Jackson, WY4.08MShares$58.2 Million93.82% of portfolio
-
Nextech Invest Ag4.06MShares$57.9 Million10.51% of portfolio
-
Nextech Invest, Ltd. Zurich, V84.06MShares$57.9 Million7.35% of portfolio
-
Bvf Inc San Francisco, CA3.94MShares$56.3 Million1.48% of portfolio
-
Canaan Partners Xi LLC Menlo Park, CA3.61MShares$51.5 Million96.23% of portfolio
-
Commodore Capital LP New York, NY3.1MShares$44.2 Million2.77% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.9MShares$41.4 Million5.66% of portfolio
-
Janus Henderson Group PLC London, X02.86MShares$40.8 Million0.01% of portfolio
-
Vestal Point Capital, LP New York, NY2.66MShares$37.9 Million1.34% of portfolio
Latest Institutional Activity in TYRA
Top Purchases
Top Sells
About TYRA
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Insider Transactions at TYRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 15
2025
|
Alan Fuhrman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
701
+4.53%
|
$6,309
$9.13 P/Share
|
|
Jun 18
2025
|
Gilla Kaplan |
SELL
Open market or private sale
|
Direct |
9,568
-25.31%
|
$86,112
$9.78 P/Share
|
|
Jun 17
2025
|
Gilla Kaplan |
SELL
Open market or private sale
|
Direct |
10
-0.03%
|
$100
$10.35 P/Share
|
|
Jun 16
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
11,813
+0.12%
|
$118,130
$10.13 P/Share
|
|
Jun 16
2025
|
Gilla Kaplan |
SELL
Open market or private sale
|
Direct |
6,814
-15.27%
|
$68,140
$10.38 P/Share
|
|
Jun 13
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
120,167
+1.16%
|
$1,201,670
$10.2 P/Share
|
|
Jun 13
2025
|
Gilla Kaplan |
SELL
Open market or private sale
|
Direct |
15,000
-25.16%
|
$150,000
$10.31 P/Share
|
|
Jun 12
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
31,307
+0.31%
|
$313,070
$10.2 P/Share
|
|
Jun 12
2025
|
Gilla Kaplan |
SELL
Open market or private sale
|
Direct |
30,000
-33.47%
|
$300,000
$10.31 P/Share
|
|
Jun 09
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
186,850
+1.82%
|
$1,868,500
$10.19 P/Share
|
|
Jun 05
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
213,334
+2.11%
|
$2,133,340
$10.04 P/Share
|
|
Jun 04
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
997,864
+9.33%
|
$8,980,776
$9.63 P/Share
|
|
Mar 14
2025
|
Alan Fuhrman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,238
+8.08%
|
$11,142
$9.78 P/Share
|
|
Mar 14
2025
|
Todd Harris President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,241
+0.09%
|
$11,169
$9.78 P/Share
|
|
Feb 05
2025
|
Nina S Kjellson |
SELL
Open market or private sale
|
Indirect |
5,401
-0.42%
|
$70,213
$13.76 P/Share
|
|
Jan 23
2025
|
Nina S Kjellson |
SELL
Open market or private sale
|
Indirect |
4,825
-0.13%
|
$77,200
$16.26 P/Share
|
|
Jan 21
2025
|
Nina S Kjellson |
SELL
Open market or private sale
|
Indirect |
3,993
-0.11%
|
$63,888
$16.36 P/Share
|
|
Jan 17
2025
|
Nina S Kjellson |
SELL
Open market or private sale
|
Indirect |
13,269
-0.22%
|
$212,304
$16.4 P/Share
|
|
Jan 16
2025
|
Nina S Kjellson |
SELL
Open market or private sale
|
Indirect |
7,779
-0.19%
|
$124,464
$16.29 P/Share
|
|
Nov 25
2024
|
Nina S Kjellson |
SELL
Open market or private sale
|
Indirect |
5,272
-0.13%
|
$84,352
$16.84 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 2.79M shares |
|---|---|
| Grant, award, or other acquisition | 3.18K shares |
| Other acquisition or disposition | 1M shares |
|---|---|
| Open market or private sale | 448K shares |
| Sale (or disposition) back to the issuer | 2M shares |